

Press Release 07.2017

Oncoinvent AS

Gullhaugveien 7

N-0484 Oslo, Norway

Tlf: (+47) 22 18 33 05

oncoinvent@oncoinvent.com

Org. nr. 995764458

www.oncoinvent.com

Radspherin[®] EU patent and OI-3 antibody US patent issued

Oslo 15. November 2017



Oncoinvent announced today that European Patent 3111959 entitled "Radiotherapeutic particles and suspensions" has issued. This patent provides patent protection for the company's lead product candidate Radspherin[®] in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

The company further announced that US Patent 9,782,500 entitled "Monoclonal Antibody and Derivatives" has issued. The patent relates to Oncoinvent's novel anti-CD146 antibody, OI-3 and derivatives that can be used for therapy and imaging, diagnosis and immunostaining. CD146 is an antigen that is up-regulated in numerous cancers including melanoma, prostate cancer, breast cancer and lung cancer.

Jan A. Alfheim, Oncoinvent's CEO commented: "This is significant milestone in both the development of our lead product candidate, Radspherin[®] as well as development of our pipeline of follow on product candidates behind Radspherin[®]. With the Radspherin[®] patent issuing in Europe we have secured protection of Radspherin[®] until 2035 in most of the major future markets for the product." Alfheim continued, "The issuance of our OI-3 antibody patent in the USA provides Oncoinvent a patent protection of potential novel OI-3 cancer



immunotherapies, as well as potential radioimmunotherapies based on a combination our Ra-224 radioisotope technology platform and the OI-3 antibody.”

About Radspherin®

Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

About Oncoinvent

Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:

Jan A. Alfheim, Chief Executive Officer

Cell: +47 46 44 00 45

Email: Alfheim@oncoinvent.com

IR enquiries:

Ole Peter Nordby, Chief Financial Officer

Cell: +47 41 28 71 79

Email: nordby@oncoinvent.com